BioPharma Resources

Therapeutic area

Endocrinology and women's health

Thyroid, growth, adrenal and reproductive conditions, menopause and contraception. Drugs are placed in areas by keyword matches on their FDA pharmacologic class and approved use, and trials by their listed conditions, so a few land in the wrong area.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations

Approvals since 2023

14

Originals, plus breakthrough or accelerated new uses

Recruiting Phase 2

8

Industry-sponsored

Recruiting Phase 3

8

Industry-sponsored

Recruiting Phase 4 (post-approval)

2

Industry-sponsored

Recent approvals

All
  • Gwyn Lo (Ethinyl Estradiol, Norelgestromin) · Viatris Specialty Jul 28, 2026
  • Lumvoa (Veligrotug-Vvze) · Viridian Therapeutics INC NovelBreakthrough therapyPriority reviewJun 26, 2026

    To treat thyroid eye disease

  • Veppanu (Vepdegestrant) · Rigel Pharms NovelMay 1, 2026

    To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy

  • Lynkuet (Elinzanetant) · Bayer Hlthcare NovelOct 24, 2025

    To treat moderate-to-severe vasomotor symptoms due to menopause

  • Inluriyo (Imlunestrant Tosylate) · Eli Lilly and CO NovelSep 25, 2025

    To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy

  • Palsonify (Paltusotine Hydrochloride) · Crinetics NovelOrphanSep 25, 2025

    To treat acromegaly in adults who had an inadequate response to surgery and/or for whom surgery is not an option

  • Miudella (Copper) · Sebela Womens Hlth Feb 24, 2025
  • Crenessity (Crinecerfont) · Neurocrine NovelBreakthrough therapyPriority reviewOrphanDec 13, 2024

    To treat classic congenital adrenal hyperplasia

  • Yorvipath (Palopegteriparatide) · Ascendis Pharma Bone NovelPriority reviewOrphanAug 9, 2024

    To treat hypoparathyroidism

  • Rezdiffra (Resmetirom) · Madrigal NovelBreakthrough therapyAccelerated approvalPriority reviewMar 14, 2024

    To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring

  • Ngenla (Somatrogon-Ghla) · Pfizer Ireland Pharmaceuticals NovelOrphanJun 27, 2023

    To treat growth failure due to inadequate secretion of endogenous growth hormone

  • Veozah (Fezolinetant) · Astellas NovelPriority reviewMay 12, 2023

    To treat moderate to severe hot flashes caused by menopause

  • Adrenalin (Epinephrine) · Ph Health Apr 21, 2023
  • Orserdu (Elacestrant Hydrochloride) · Stemline Therap NovelPriority reviewJan 27, 2023

    To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy

Drugs in development

Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.

All
  • GiredestrantRO7197597, GDC-9545Phase 316 trials

    Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

  • ZanzalintinibXL092Phase 311 trials

    Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • AtirmociclibPF-07220060Phase 39 trials

    Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer

  • LHRH AgonistPhase 36 trials

    Roche (Genentech) · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer, Early Breast Cancer, Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

  • LUM-201Phase 36 trials

    Lumos Pharma · Growth Hormone Deficiency, Growth Hormone Deficiency (GHD), Obesity & Overweight

  • MHB018APhase 36 trials

    Minghui Pharmaceutical (Hangzhou) Ltd · Thyroid Eye Disease (TED), Thyroid Eye Disease, TED, Thyroid Associated Ophthalmopathies

  • CRN04894AtumelnantPhase 35 trials

    Crinetics Pharmaceuticals Inc. · Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia, Cushing Syndrome

  • VRDN-003ZL-1109Phase 35 trials

    Viridian Therapeutics, Inc. · Thyroid Eye Disease, Thyroid Eye Disease (TED)

  • InpegsomatropinPhase 34 trials

    Xiamen Amoytop Biotech Co., Ltd. · Turner Syndrome, Idiopathic Short Stature, Adult Growth Hormone Deficiency

  • ZN-c3azenosertibPhase 34 trials

    K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Ovarian Cancer, High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer, Uterine Serous Carcinoma

  • AL2846Phase 33 trials

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Thyroid Cancer, Differentiated Thyroid Cancer, Advanced Lung Cancer

  • BatoclimabIMVT-1401Phase 33 trials

    Immunovant Sciences GmbH · Thyroid Eye Disease, Graves Disease

  • CAM2029octreotide depotPhase 33 trials

    Camurus AB · Polycystic Liver Disease, Gastro-enteropancreatic Neuroendocrine Tumor, Acromegaly

  • EncaleretCLTX-305Phase 33 trials

    Calcilytix Therapeutics, Inc., a BridgeBio company · Autosomal Dominant Hypocalcemia Type 1 (ADH1), Autosomal Dominant Hypocalcemia (ADH), Hypoparathyroidism

  • IBI311Phase 33 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Thyroid Eye Disease, Thyroid Eye Disease, TED

Largest recruiting Phase 3 trials

All

More: Endocrinology and women's health news · literature

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.